|Issue Date||09/11 - 11/11|
|Issue Size||₹6479.55 Cr|
|Issue Price||₹1490 - 1500|
|Market Lot||10 Shares|
|Shares on Offer||34,863,635|
|GMP||₹160 - 170|
|Subject to Sauda||₹1350-1400|
|Listing Date||20 Nov 2020|
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. They operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. They are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
A holistic objective of dispensing health through a portfolio of injectable products across various therapeutic segments and delivery systems, has helped us expand to seven manufacturing facilities in India, with a capacity of approximately 750 million units. These include ftheir facilities with 22 production lines for finished formulations and three Active Pharmaceutical Ingredient (API) facilities. Their products are produced at world-class manufacturing facilities and conform to global compliance, regulatory and quality specifications.
They are present in sterile injectables, oncology and ophthalmic segments, and focus on complex injectables including NCE-1s, First-to-File products and 505(b)(2) filings. Their products are currently delivered via liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops; and efforts are underway to augment additional manufacturing capabilities in complex injectables such as peptides, long-acting injectables, suspensions and hormonal products. They are also in the process of including new delivery systems such as pens and cartridges into their product portfolio.
Their ethos at work is to consistently focus on meeting diverse injectable needs with high-quality products at attractive price points. On this strong plinth of looking ahead, they have successfully and repeatedly harnessed their R&D expertise in synthesizing complex molecules to produce complex injectables. Enabling us to develop niche products for diverse markets worldwide.
Fosun Pharma Industrial Pte. Ltd and Shanghai Fosun Pharmaceutical (Group) Co. Ltd is the company promoters.
The net proceeds from the IPO will be used for the following purposes:
|Total Assets (In ₹ Millions)||40,860.39||35,235.49||29,294.68|
|Total Revenue (In ₹ Millions)||27,724.08||21,297.67||16,716.82|
|Profit After Tax (PAT) (In ₹ Millions)||7,728.58||4,518.56||3,210.51|
|Date & Time||QIB||NII||RII||Total|
|Day 1 - 09 Nov 2020|
|Day 2 - 10 Nov 2020|
|Day 3 - 11 Nov 2020|
Please click the link below to check the IPO allotment status.IPO Allotment Status
Gland Pharma Limited IPO will open on 09/11 and close on 11/11.
Gland Pharma Limited IPO will list on 20 Nov 2020.
The offer price of Gland Pharma Limited IPO is ₹1490 - 1500.
The lot size of Gland Pharma Limited IPO is 10.
The Grey Market Premium (GMP) price of Gland Pharma Limited IPO is ₹160 - 170.
The Kostak price of Gland Pharma Limited IPO is ₹800.
The Subject to Sauda price for Gland Pharma Limited IPO is ₹1350-1400.
Please Leave Your Message